Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.
|Videos|May 12, 2020
Dr. Trent on the Impact of COVID-19 on the Treatment of Rare Cancers
Author(s)Jonathan C. Trent, MD, PhD
Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.
Advertisement
Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, sheds light on the impact of COVID-19 on the treatment of rare cancers.
Please visit
Advertisement
Related to this article
Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5